{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:10:24Z","timestamp":1779426624529,"version":"3.53.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejphar.2026.178699","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:21:53Z","timestamp":1772209313000},"page":"178699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dinaciclib reduces MCL-1 levels and triggers apoptosis in adult T-cell leukemia\/lymphoma"],"prefix":"10.1016","volume":"1019","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5855-5285","authenticated-orcid":false,"given":"Gunya","family":"Sittithumcharee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusho","family":"Kariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwanon","family":"Jirawatnotai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-5206","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178699_bib1","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1074\/jbc.M610643200","article-title":"Rapid turnover of mcl-1 couples translation to cell survival and apoptosis","volume":"282","author":"Adams","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.178699_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678559","article-title":"CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents","volume":"11","author":"Anshabo","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2026.178699_bib3","first-page":"1787","article-title":"Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus","volume":"26","author":"Attia","year":"1966","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178699_bib4","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/0008-5472.CAN-15-1070","article-title":"The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia","volume":"76","author":"Baker","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178699_bib5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/path.1588","article-title":"CDK9\/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation","volume":"203","author":"Bellan","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejphar.2026.178699_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/1878-0261.13522","article-title":"Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-X(L) in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients","author":"Beltr\u00e1n-Visiedo","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejphar.2026.178699_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108371","article-title":"MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis","volume":"9","author":"Booher","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178699_bib8","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1038\/s41598-021-84082-3","article-title":"Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells","volume":"11","author":"Buzzetti","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178699_bib9","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1182\/blood-2008-12-190256","article-title":"Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia","volume":"113","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178699_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004458","article-title":"HTLV-1 tax stabilizes MCL-1 via TRAF6-Dependent K63-Linked polyubiquitination to promote cell survival and transformation","volume":"10","author":"Choi","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejphar.2026.178699_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4161\/cbt.4.3.1497","article-title":"Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors","volume":"4","author":"De Falco","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejphar.2026.178699_bib12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00280-014-2583-9","article-title":"Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed\/refractory chronic lymphocytic leukemia patients","volume":"74","author":"Fabre","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178699_bib13","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/leu.2015.31","article-title":"Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia","volume":"29","author":"Flynn","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2026.178699_bib14","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2016-10-748210","article-title":"Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"129","author":"Ghia","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178699_bib15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00280-013-2249-z","article-title":"Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias","volume":"72","author":"Gojo","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178699_bib16","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2021005872","article-title":"Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study","volume":"6","author":"Gregory","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejphar.2026.178699_bib17","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1002\/eji.200535125","article-title":"Selective expansion and engraftment of human CD16+ NK cells in NOD\/SCID mice","volume":"35","author":"Harada","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejphar.2026.178699_bib18","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1111\/cas.14658","article-title":"Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study","volume":"111","author":"Imaizumi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2026.178699_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.canlet.2011.11.030","article-title":"Targeting Bcl-2 family proteins in adult T-cell leukemia\/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737","volume":"317","author":"Ishitsuka","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2026.178699_bib20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fmicb.2012.00322","article-title":"Adult T-cell leukemia: a review of epidemiological evidence","volume":"3","author":"Iwanaga","year":"2012","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejphar.2026.178699_bib21","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/leu.2012.144","article-title":"The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells","volume":"26","author":"Johnson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2026.178699_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3960\/jslrt.17008","article-title":"Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma","volume":"57","author":"Katsuya","year":"2017","journal-title":"J. Clin. Exp. Hematop."},{"key":"10.1016\/j.ejphar.2026.178699_bib23","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178699_bib24","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood.V94.11.3847","article-title":"Inhibition of caspase Cascade by HTLV-I tax through induction of NF-\u03baB nuclear translocation","volume":"94","author":"Kawakami","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178699_bib25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ijc.20954","article-title":"Transcriptional activation of survivin through the NF-\u03baB pathway by human T-cell leukemia virus type I tax","volume":"115","author":"Kawakami","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.178699_bib26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178699_bib27","doi-asserted-by":"crossref","first-page":"9978","DOI":"10.1074\/jbc.M002285200","article-title":"Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation","volume":"276","author":"Lee","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.178699_bib28","article-title":"Inhibitory response to CK II inhibitor silmitasertib and CDKs inhibitor dinaciclib is related to genetic differences in pancreatic ductal adenocarcinoma cell lines","volume":"23","author":"Ma","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178699_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092181","article-title":"Targeting CDK9 for anti-cancer therapeutics","author":"Mandal","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2026.178699_bib48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","article-title":"Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1","volume":"6","author":"Maurer","year":"2006","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejphar.2026.178699_bib30","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/bjc.2017.288","article-title":"Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies","volume":"117","author":"Mita","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.178699_bib31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s10637-015-0244-4","article-title":"A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer","volume":"33","author":"Mitri","year":"2015","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejphar.2026.178699_bib32","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1128\/MCB.00450-16","article-title":"Enhanced stabilization of MCL1 by the human T-Cell leukemia virus type 1 bZIP factor is modulated by blocking the recruitment of cullin 1 to the SCF complex","volume":"36","author":"Mukai","year":"2016","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2026.178699_bib33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/cts.12802","article-title":"A phase I study of dinaciclib in combination with MK-2206 in patients with advanced pancreatic cancer","volume":"13","author":"Murphy","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejphar.2026.178699_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.ejphar.2026.178699_bib35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2016-09-741983","article-title":"Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia\/lymphoma","volume":"130","author":"Narita","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178699_bib36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1479-5876-11-259","article-title":"A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies","volume":"11","author":"Nemunaitis","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.178699_bib49","article-title":"Comparative study of human hematopoietic cell engraftment into BALB\/c and C57BL\/6 strain of rag-2\/jak3 double-deficient mice","volume":"539748","author":"Ono","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ejphar.2026.178699_bib37","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2026.178699_bib38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11899-018-0458-6","article-title":"Adult T cell leukemia-lymphoma (ATL): state of the art","volume":"13","author":"Phillips","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.ejphar.2026.178699_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5858\/arpa.2012-0379-RS","article-title":"Adult T-cell leukemia\/lymphoma","volume":"138","author":"Qayyum","year":"2014","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ejphar.2026.178699_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2020.00055","article-title":"Activation of the kynurenine pathway in human malignancies can be suppressed by the cyclin-dependent kinase inhibitor dinaciclib","volume":"11","author":"Riess","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178699_bib41","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1002\/ptr.7322","article-title":"Antitumor effect of acanthoic acid against primary effusion lymphoma via inhibition of c-FLIP","volume":"35","author":"Sittithumcharee","year":"2021","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejphar.2026.178699_bib42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2013.11.020","article-title":"Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer","volume":"83","author":"Stephenson","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejphar.2026.178699_bib43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/0008-5472.CAN-13-0436","article-title":"HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization","volume":"74","author":"Tanaka-Nakanishi","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178699_bib44","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1128\/JVI.73.10.7981-7987.1999","article-title":"Induction of Bcl-x(L) expression by human T-Cell leukemia virus type 1 tax through NF-kappaB in apoptosis-resistant T-Cell transfectants with tax","volume":"73","author":"Tsukahara","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2026.178699_bib45","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1128\/JVI.03025-13","article-title":"Human T-Cell leukemia virus type 1 tax-deregulated autophagy pathway and c-FLIP expression contribute to resistance against death receptor-mediated apoptosis","volume":"88","author":"Wang","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2026.178699_bib46","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1128\/JVI.00079-11","article-title":"Ubiquitin-specific peptidase 20 targets TRAF6 and human T cell leukemia virus type 1 tax to negatively regulate NF-kappaB signaling","volume":"85","author":"Yasunaga","year":"2011","journal-title":"J. Virol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926001810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926001810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:59:22Z","timestamp":1779425962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926001810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":48,"alternative-id":["S0014299926001810"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178699","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dinaciclib reduces MCL-1 levels and triggers apoptosis in adult T-cell leukemia\/lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178699"}}